GlassScriptPhysician profile
Kevin Patel
NPI 1720474463
$3,281.75
in general payments reported to CMS, 2019-2025
9 companies · $608 in 2025
The $608 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2021: $115 · 2022: $1,151 · 2023: $572 · 2024: $619 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.90 |
| Education | $163.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $1,087.85 | 2022-2024 | Remede System |
| Inspire Medical Systems, INC. | $832.36 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $685.40 | 2022-2025 | Xywav |
| Insmed, INC. | $216.57 | 2019 | |
| Harmony Biosciences LLC | $122.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $115.00 | 2021 | |
| Glaxosmithkline, LLC. | $102.00 | 2023 | Nucala |
| Avadel Cns Pharmaceuticals, LLC | $99.80 | 2024 | Lumryz |
| Olympus America INC. | $20.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.